Ask Warren

SK Bioscience

302440 · KOSPI · ₩302440 · SK바이오사이언스

₩32,200▲ ₩50 (0.16%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩156B₩169B₩184B₩151B₩162B₩155B₩157B₩62B
Cost of sales₩114B₩154B₩179B₩118B₩150B₩128B₩151B₩60B
Gross profit₩42B₩15B₩5B₩33B₩12B₩26B₩5.6B₩1.8B
Operating income−₩16B−₩45B−₩52B−₩19B−₩37B−₩15B−₩51B−₩40B
Net income₩22B−₩36B−₩77B₩38B−₩13B−₩4.1B−₩28B−₩11B
Net income to shareholders−₩18B−₩33B−₩58B₩24B−₩16B−₩7.5B−₩6.4B−₩22B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩3T₩3T₩3T₩2.9T₩2.9T₩2.9T₩2.8T₩2T
Current assets₩1.2T₩1.3T₩1.2T₩1.4T₩1.4T₩1.6T₩1.6T₩1.5T
Cash and equivalents₩130B₩87B₩106B₩160B₩243B₩306B₩313B₩512B
Total liabilities₩975B₩968B₩918B₩848B₩830B₩862B₩821B₩328B
Current liabilities₩334B₩310B₩326B₩322B₩320B₩348B₩311B₩129B
Borrowings₩528B₩534B₩465B₩406B₩396B₩395B₩383B₩188B
Total equity₩2T₩2T₩2T₩2.1T₩2T₩2T₩2T₩1.7T
Shareholders' equity₩1.7T₩1.8T₩1.8T₩1.8T₩1.8T₩1.8T₩1.8T₩1.7T

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩2.7B−₩43B₩24B₩21B−₩4.6B₩63B−₩13B−₩43B
Capital spending₩27B₩37B₩30B₩45B₩65B₩43B₩48B₩33B
Free cash flow−₩25B−₩79B−₩6.3B−₩25B−₩70B₩20B−₩61B−₩76B

Consolidated where available. Amounts in won.

Also known as: SK Bioscience / SK바이오사이언스 / 302440 / KRX:302440

Source: KRX statistical information